CG Oncology/$CGON
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CG Oncology
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Ticker
$CGON
Sector
Primary listing
Employees
142
Headquarters
Website
CG Oncology Metrics
BasicAdvanced
$5.4B
-
-$2.08
1.19
-
Price and volume
Market cap
$5.4B
Beta
1.19
52-week high
$64.70
52-week low
$14.80
Average daily volume
1.1M
Financial strength
Current ratio
24.629
Quick ratio
24.09
Long term debt to equity
0.811
Total debt to equity
0.933
Profitability
EBITDA (TTM)
-189.329
Gross margin (TTM)
-2,902.18%
Net profit margin (TTM)
-3,985.02%
Operating margin (TTM)
-4,722.13%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-15.42%
Return on equity (TTM)
-21.67%
Valuation
Price to revenue (TTM)
1,230.172
Price to book
6.89
Price to tangible book (TTM)
6.99
Price to free cash flow (TTM)
-37.514
Free cash flow yield (TTM)
-2.67%
Free cash flow per share (TTM)
-1.714
Growth
Revenue change (TTM)
254.70%
Earnings per share change (TTM)
47.84%
3-year revenue growth (CAGR)
176.56%
3-year earnings per share growth (CAGR)
-43.76%
What the Analysts think about CG Oncology
Analyst ratings (Buy, Hold, Sell) for CG Oncology stock.
CG Oncology Financial Performance
Revenues and expenses
CG Oncology Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CG Oncology stock?
CG Oncology (CGON) has a market cap of $5.4B as of March 17, 2026.
What is the P/E ratio for CG Oncology stock?
The price to earnings (P/E) ratio for CG Oncology (CGON) stock is 0 as of March 17, 2026.
Does CG Oncology stock pay dividends?
No, CG Oncology (CGON) stock does not pay dividends to its shareholders as of March 17, 2026.
When is the next CG Oncology dividend payment date?
CG Oncology (CGON) stock does not pay dividends to its shareholders.
What is the beta indicator for CG Oncology?
CG Oncology (CGON) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.